|
Market Cap (13-Jul) $6,957,488 (1,468th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 582,113 |
Shortsold (6-Dec) 611,822 (0.21%) (374th) |
|
52w High $0.079 |
52w Low $0.015 |
P/E - |
EPS -0.02 |
ACR released this announcement to the ASX on 30 January 2023, 9:20. The announcement is marked as price sensitive, and is 7 page(s) in length and 324.06kb in size.
You can view all announcements from ACR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACR was 0.004% short sold according to ASIC data. It was ranked the 605th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).
| Other Recent Announcements from ACR | |
|---|---|
| Appendix 3Y Brooke | 16 June 2023, 9:27 |
| Application for quotation of securities - ACR | 16 June 2023, 9:25 |
| 4th FDA ANDA approval received - Dapsone Gel, 5% | 7 June 2023, 10:35 |
| Quarterly Activities / Appendix 4C Cashflow Report | 30 January 2023, 9:20 |
| Gedeon Richter buyout Lenzetto Royalties for EUR4.1million | 23 January 2023, 8:59 |
| Positive FDA Remote Regulatory Assessment | 19 January 2023, 9:20 |
| Launch of prilocaine and lidocaine cream in United States | 21 December 2022, 8:29 |
You must be logged in to post a reply.
